Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

OBJECTIVE: Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed safety and efficacy of BIF versus degludec in 265 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazda, Christof M., Bue-Valleskey, Juliana M., Chien, Jenny, Zhang, Qianyi, Chigutsa, Emmanuel, Landschulz, William, Wullenweber, Paula, Haupt, Axel, Dahl, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154655/
https://www.ncbi.nlm.nih.gov/pubmed/36920867
http://dx.doi.org/10.2337/dc22-2395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154655/
https://www.ncbi.nlm.nih.gov/pubmed/36920867
http://dx.doi.org/10.2337/dc22-2395

Ejemplares similares